GlassScriptPhysician profile
Anna T Mcnay
NPI 1619947488
$23,738.03
in general payments reported to CMS, 2019-2025
31 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $1,373 · 2021: $3,609 · 2022: $2,213 · 2023: $8,067 · 2024: $3,338 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,993 · Consulting Fee: $4,095 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,791 · Travel and Lodging: $253 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,993.09 |
| Consulting Fee | $4,095.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,791.10 |
| Travel and Lodging | $252.91 |
| Education | $243.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,120.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,467.65 | 2022-2024 | Sotyktu |
| Allergan, INC. | $3,318.79 | 2019-2023 | |
| Janssen Biotech, INC. | $1,002.14 | 2019-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $928.21 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $823.20 | 2022-2024 | Vtama |
| Genzyme Corporation | $720.28 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $713.41 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $671.84 | 2019-2020 | |
| Pfizer INC. | $594.21 | 2019-2025 | |
| Amgen INC. | $519.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.38 | 2022-2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $424.85 | 2019-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $384.76 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $352.84 | 2019-2025 | Jublia, Arazlo, Cabtreo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $322.93 | 2019-2025 | Dysport |
| Vyne Pharmaceuticals INC. | $302.31 | 2020-2021 | |
| Epi Health, LLC | $257.23 | 2019-2021 | |
| Genentech USA, INC. | $234.96 | 2019-2021 | |
| Sandoz INC. | $164.34 | 2019-2020 | |
| Ucb, INC. | $162.95 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $147.73 | 2019-2025 | |
| Leo Pharma INC. | $132.15 | 2021-2025 | Adbry, Spevigo |
| Arcutis Biotherapeutics, INC. | $111.87 | 2023-2025 | Zoryve |
| Almirall LLC | $101.34 | 2019-2025 | Klisyri |
| Journey Medical Corporation | $93.40 | 2021-2023 | |
| Dermira, INC. | $79.36 | 2019-2020 | |
| Organon LLC | $75.31 | 2025 | |
| Biofrontera INC. | $32.79 | 2019-2020 | |
| Hill Dermaceuticals, INC. | $21.42 | 2025 | Tolak |
| Mission Pharmacal Company | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mcnay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.